宏基因组学揭示IL-17抑制剂治疗银屑病关节炎患者肠道微生物群的进化。

IF 3.8 3区医学 Q1 RHEUMATOLOGY

Joint Bone Spine Pub Date : 2025-02-25 DOI:10.1016/j.jbspin.2025.105868

Wei Liu , Yan Geng , Yu Wang , Juan Zhao , Yong Fan , Xiaohui Zhang , Wenhui Xie , Liang Zhang , Zhuoli Zhang

{"title":"宏基因组学揭示IL-17抑制剂治疗银屑病关节炎患者肠道微生物群的进化。","authors":"Wei Liu , Yan Geng , Yu Wang , Juan Zhao , Yong Fan , Xiaohui Zhang , Wenhui Xie , Liang Zhang , Zhuoli Zhang","doi":"10.1016/j.jbspin.2025.105868","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To explore the evolution of gut microbiota in taxonomy and function in PsA patients during IL-17i treatment.</div></div><div><h3>Methods</h3><div>Twenty PsA patients treated with secukizumab were included. Fecal samples were collected before treatment (0 mo.), first month (1 mo.) and third month (3 mo.) after treatment, and a total of 60 samples were collected. Shotgun metagenomic sequencing was used to detect all fecal samples.</div></div><div><h3>Results</h3><div>In the 1 mo. and 3 mo. after IL-17i treatment, the disease activity in PsA patients decreased significantly. Compared with 0 mo., α-diversity calculated by Shannon index and Pielou index increased significantly at 1 mo. and 3 mo. after treatment. Microbial genes encoding Carbohydrate-Active enZymes (CAZymes) tended to be upregulated after treatment. After treatment, <em>Bacteroidota</em> phylum expanded, especially the abundance of <em>Phocaeicola</em> genus increased gradually with the treatment time (<em>P</em>  <0.05). The abundance of <em>Phocaeicola</em> genus was positively correlated with the α-diversity. The Polysaccharide Lyases and Carbohydrate Esterases in CAZymes were significantly positively correlated with most of species in <em>Phocaeicola</em> genus.</div></div><div><h3>Conclusions</h3><div>Treatment with IL-17i induces gut microbiota evolution in PsA patients. The key features of this evolution include increased α-diversity, expansion of the <em>Phocaeicola</em> genus, and upregulation of CAZymes. Species within the <em>Phocaeicola</em> genus may be the critical bacteria driving this evolution.</div></div>\",\"PeriodicalId\":54902,\"journal\":{\"name\":\"Joint Bone Spine\",\"volume\":\"92 4\",\"pages\":\"Article 105868\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-02-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Joint Bone Spine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1297319X25000272\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Joint Bone Spine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297319X25000272","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：探讨IL-17i治疗期间PsA患者肠道菌群在分类和功能方面的演变。方法：纳入20例接受塞库珠单抗治疗的PsA患者。分别于治疗前（0个月）、治疗后第1个月（1个月）和治疗后第3个月（3个月）采集粪便样本，共采集60份样本。采用散弹枪宏基因组测序对所有粪便样本进行检测。结果：在IL-17i治疗后1、3个月，PsA患者的疾病活动性明显降低。与0个月相比，处理后1个月Shannon指数和3个月Pielou指数计算的α-多样性显著增加。编码碳水化合物活性酶（CAZy）的微生物基因在处理后趋于上调。治疗后，随着治疗时间的延长，拟杆菌门逐渐扩大，尤其是Phocaeicola属的丰度逐渐增加(结论：IL-17i治疗可诱导PsA患者肠道微生物群进化。这一进化的主要特征包括α-多样性的增加、Phocaeicola属的扩展和CAZy的上调。Phocaeicola属的物种可能是推动这种进化的关键细菌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evolution of gut microbiota in psoriatic arthritis treated with IL-17 inhibitor revealed by metagenomics

Objectives

To explore the evolution of gut microbiota in taxonomy and function in PsA patients during IL-17i treatment.

Methods

Twenty PsA patients treated with secukizumab were included. Fecal samples were collected before treatment (0 mo.), first month (1 mo.) and third month (3 mo.) after treatment, and a total of 60 samples were collected. Shotgun metagenomic sequencing was used to detect all fecal samples.

Results

In the 1 mo. and 3 mo. after IL-17i treatment, the disease activity in PsA patients decreased significantly. Compared with 0 mo., α-diversity calculated by Shannon index and Pielou index increased significantly at 1 mo. and 3 mo. after treatment. Microbial genes encoding Carbohydrate-Active enZymes (CAZymes) tended to be upregulated after treatment. After treatment, Bacteroidota phylum expanded, especially the abundance of Phocaeicola genus increased gradually with the treatment time (P < 0.05). The abundance of Phocaeicola genus was positively correlated with the α-diversity. The Polysaccharide Lyases and Carbohydrate Esterases in CAZymes were significantly positively correlated with most of species in Phocaeicola genus.

Conclusions

Treatment with IL-17i induces gut microbiota evolution in PsA patients. The key features of this evolution include increased α-diversity, expansion of the Phocaeicola genus, and upregulation of CAZymes. Species within the Phocaeicola genus may be the critical bacteria driving this evolution.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Joint Bone Spine 医学-风湿病学

CiteScore

4.50

自引率

11.90%

发文量

184

审稿时长

25 days

期刊介绍： Bimonthly e-only international journal, Joint Bone Spine publishes in English original research articles and all the latest advances that deal with disorders affecting the joints, bones, and spine and, more generally, the entire field of rheumatology. All submitted manuscripts to the journal are subjected to rigorous peer review by international experts: under no circumstances does the journal guarantee publication before the editorial board makes its final decision. (Surgical techniques and work focusing specifically on orthopedic surgery are not within the scope of the journal.)Joint Bone Spine is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.